Immuno-Oncology: Unicorns, China And The Perfect Storm

Thanks to a confluence of favorable factors, immuno-oncology’s capital markets are booming, having been flooded by venture capitalist investments that are driving development. The result: the market is seeing fewer deals, but on a larger scale, and with a shortened path to an exit. Understand the trends for immuno-oncology transactions, investigate institutional investor activity in the area, and gain a view into the exit landscape for investors as you gather key takeaways for investment in the IO area with this insightful article from In Vivo.